Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".

Mazza, Mario Gennaro; Vai, Benedetta; De Picker, Livia; Benedetti, Francesco; Zanardi, Raffaella

Mazza, Mario Gennaro; Vai, Benedetta; De Picker, Livia; Benedetti, Francesco; Zanardi, Raffaella.

Mazza MG; Psychiatry and Clinical Psychobiology, Division of Neuroscience, Dipartimento di Neuroscienze Cliniche, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy. mazza.mariogennaro@hsr.it.
Vai B; Vita-Salute San Raffaele University, Milan, Italy. mazza.mariogennaro@hsr.it.
De Picker L; Psychiatry and Clinical Psychobiology, Division of Neuroscience, Dipartimento di Neuroscienze Cliniche, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy.
Benedetti F; Vita-Salute San Raffaele University, Milan, Italy.
Zanardi R; University Psychiatric Hospital Campus Duffel, Duffel, Belgium.

Drugs ; 82(3): 349-351, 2022 02.

Article in English | MEDLINE | ID: covidwho-1682240

Subject(s)

COVID-19 Drug Treatment; Fluvoxamine; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluvoxamine / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Drugs Year: 2022 Document Type: Article Affiliation country: S40265-022-01682-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google